Northwestern Medicine®

Background

- There prevalence of chronic comorbid conditions is increasing amongst the general population in the United States
- Obesity (body mass index $>30 \text{ kg/m}^2$) affects >40% of the population Hypertension is present in up to 45% of the population
- Diabetes affects 10-12% of the population (*data from www.cdc.gov*) Chronic medical conditions are associated with end-organ damage which
- may affect quality of organs prior to donation

Aims of the present study:

- To determine if changes in the donor population were reflective of changes in the health of the general population
- . To evaluate the effects of changing donor health on donor and organ utilization

Methods

Study Population

UNOS/OPTN Standard Transplant Analysis and Research (STAR) file

- 132,783 potential organ donors identified between 2005-2019
- Included all ages and donation types (DBD vs DCD)
- Evaluated demographic characteristics, medical and social history, and terminal laboratory values

Donor Utilization– determined by transplantation of at least one organ from a single donor


Data Analysis

- Three Eras: Era 1 (2005-2009), Era 2 (2010-2014), Era 3 (2015-2019)
- Donor characteristics compared using T-tests, ANOVA, and Wilcoxon Rank-Sum tests as appropriate
- Multi-Variable Modeling-- Logistic Regression for Donor Utilization • Donors cohorted by donor type (DBD vs DCD)
- Created individual models for each era
- Created a composite model to evaluate across eras

x- history; INR- international normalized ratio; MI- myocardial infarction

^aHistory of smoking >20 pack-years


Donor Characteristics	2005-2009 (n= 39,728)	2010-2014 (n= 41,100)	2015-2019 (n= 51,955)	p-Values					
Age, years	43 (24.5 - 55)	42 (25 - 54)	41 (27 – 62)	0.002					
(median, IQR)	45 (24.5 - 55)	42 (23 - 54)	41(27-02)	0.002					
Gender, female (n, %)	16,186 (40.7%)	16,753 (40.7%)	20,663 (39.7%)	0.001					
BMI, kg/m ²	25.8 (22.4 - 30.2)	26.5 (22.8 - 31.1)	26.9 (23.1 - 31.8)	< 0.001					
BMI >30 kg/m ²	9,259 (25.7%)	10,525 (29.6%)	13,666 (32.5%)	< 0.001					
Ethnicity				< 0.001					
White	26,758 (67.3%)	27,261 (66.3%)	34,241 (65.8%)						
Black	6,259 (15.8%)	7,086 (17.2%)	8,501 (16.4%)						
Hispanic	5,574 (14.0%)	5,517 (13.4%)	7,440 (14.3%)						
Asian	892 (2.2%)	995 (2.4%)	1,329 (2.6%)						
Other	262 (0.7%)	261 (0.6%)	496 (1.0%)						
Blood Type				0.695					
0	19,136 (48.2%)	19,629 (47.7%)	24,937 (48.0%)						
А	14,603 (36.7%)	15,111 (36.8%)	19,201 (36.9%)						
В	4,656 (11.7%)	4,954 (12.1%)	6,102 (11.7%)						
AB	1,348 (3.4%)	1,423 (3.5%)	1,764 (3.4%)						
DCD Donor	3,768 (9.5%)	5,607 (13.6%)	9,930 (19.1%)	< 0.001					
Cause of Death				< 0.001					
Anoxia	7,620 (19.2%)	12,177 (29.6%)	21,809 (41.9%)						
Trauma	14,466 (36.4%)	13,375 (32.5%)	14,353 (27.6%)						
CVA/Stroke	16,391 (41.2%)	14,364 (34.9%)	14,243 (27.4%)						
Other	1,268 (3.2%)	1,204 (2.9%)	1,602 (3.1%)						
Hx of Hypertension	13,986 (35.4%)	14,417 (35.3%)	18,133 (35.2%)	< 0.001					
Hx of Diabetes	4,344 (11.0%)	4,951 (12.1%)	6,287 (12.2%)	< 0.001					
Prior MI	1,642 (4.1%)	1,389 (3.4%)	2,153 (4.1%)	< 0.001					
HCV-Positive	1,631 (4.1%)	1,783 (4.3%)	4,053 (7.8%)	< 0.001					
HBV-Positive	2,169 (5.5%)	1,962 (4.8%)	2,636 (5.1%)	< 0.001					
Heavy Alcohol Use	6,471 (16.3%)	6,877 (16.7%)	9,674 (18.6%)	< 0.001					
Cigarette Smoker ^a	11,793 (29.7%)	9,249 (22.5%)	10,738 (20.7%)	< 0.001					
Any Drug Use	11,726 (29.5%)	16,128 (39.2%)	24,980 (48.0%)	< 0.001					
Serum Creatinine	1.0 (0.8 - 1.5)	1.0 (0.7 - 1.5)	1.0 (0.7 – 1.7)	< 0.001					
Serum AST	47 (28 - 88)	47 (28 - 91)	47 (26 - 95)	0.020					
Serum ALT	35 (22 - 66)	38 (22 - 75)	40 (22 - 83)	< 0.001					
Total Bilirubin	0.7 (0.5 – 1.2)	0.7(0.4 - 1.1)	0.7(0.4 - 1.1)	< 0.001					
INR	1.28 (1.10 – 1.43)	1.27 (1.10 – 1.40)	1.23 (1.10 - 1.40)	< 0.001					
Serum Sodium	146 (141 – 152)	147 (142 – 153)	148 (142 – 153)	< 0.001					
Abbreviations: ALT- alanine aminotransferase; AST- aspartate aminotransferase; BMI- body mass index; CVA- cerebrovascular disease; DCD- donation after circulatory death; HBV- hepatitis B virus; HCV- hepatitis C virus;									




A 12000

A Retrospective Evaluation of Organ Donation in the United States: Trends in Donors and Organ Utilization Over 15 Years Justin A Steggerda MD¹, Irene K Kim MD², and Daniel Borja-Cacho MD¹

¹Kovler Organ Transplant Center, Northwestern Memorial Hospital, Chicago, IL ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA





A) Number of donors utilized for transplant for all organs-heart, lung, liver, kidney, pancreas, and intestine.

B) Annual donor utilization rate by organ type. DBD donors only.

Figure 4. Likelihood of Donor Utilization Across Eras for DBD Donors. A composite model consisting of factors associated with donor utilization in any era was used as base model. Donor utilization was then assessed in specific marginal subgroups (i.e., older age, obese donors, comorbid conditions, etc.). Likelihood of donor utilization within each subgroup was assessed using Era 1 (2005-2009) as reference group. Odds ratios (OR) and 95% confidence intervals are shown for Era 2 (2010-2014, gray diamonds) and Era 3 (2015-2019, black diamonds). DCD donors were evaluated separately (results not shown).



preceding eras

- There is a large increase in the utilization of organs from Hepatitis C virus positive donors in 2015-2019, a result of the development of a successful treatments for HCV

$\begin{array}{c c c c c c c c c c c c c c c c c c c $		2005-2009			2010-2014			2015-2019	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	OR	95% CI	-	OR	95% CI	-	OR	95% CI	p-Value
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			<0.001			<0.001			<0.001
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		0.174 - 1.302			0.082 - 0.783			0.098 - 0.617	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	0.720	0.229 - 2.257		0.880	0.188 - 4.113		2.251	0.297 – 17.071	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Reference			Reference			Reference		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	0.310	0.157 - 0.614		0.223	0.105 - 0.472		0.720	0.387 - 1.340	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	0.206	0.110 - 0.385		0.136	0.067 - 0.276		0.260	0.145 - 0.432	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	0.140	0.075 - 0.260		0.080	0.040 - 0.161		0.118	0.070 - 0.201	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	0.052	0.028 - 0.096		0.035	0.017 - 0.071		0.064	0.037 - 0.109	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	0.024	0.012 - 0.045		0.020	0.010 - 0.042		0.031	0.018 - 0.055	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$			< 0.001			0.002			<0.001
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.716	0.431 - 1.191		0.908	0.489 - 1.687		0.643	0.343 - 1.201	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Reference			Reference			Reference		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1.127	0.887 - 1.432		1.101	0.845 - 1.433		0.834	0.644 - 1.080	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	0.731	0.574 - 0.931		0.772	0.595 - 1.000		0.711	0.551 - 0.918	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	0.407	0.282 - 0.588		0.553	0.379 - 0.808		0.380	0.273 - 0.529	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						0.003			< 0.001
$\begin{array}{c c c c c c c c c c c c c c c c c c c $				Reference			Reference		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $					1.237 - 2.157			1.218 - 2.026	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $				1.115	0.635 - 1.959		0.732	0.466 - 1.149	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $				0.525	0.190 - 1.448		0.763	0.303 - 1.922	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			0.009			0.004			< 0.001
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Reference			Reference			Reference		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	0.853	0.702 - 1.037		0.856	0.693 - 1.057		1.010	0.827 - 1.233	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		0.318 - 0.760							
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			0.002						< 0.001
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Reference						Reference		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		1.294 - 2.486						1.049 - 1.955	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			< 0.001	0.582	0.465 - 0.729	<0.001			<0.001
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$									
0.574 0.460 - 0.715 <0.001 0.618 0.493 - 0.776 <0.001 0.585 0.480 - 0.714 <0.001 0.660 0.583 - 0.810 <0.001									
0.660 0.583 - 0.810 <0.001 0.571 0.459 - 0.711 <0.001 0.571 0.462 - 0.704 <0.001 0.460 0.351 - 0.602 <0.001									
0.460 0.351 - 0.602 <0.001 0.625 0.475 - 0.820 <0.001 0.497 0.394 - 0.626 <0.001 0.487 0.400 - 0.593 <0.001									
0.487 0.400-0.593 <0.001									
	0.400	0.551 - 0.002	NO.001	0.025	0.475 - 0.820	\0.001			
ale annouansierase, divit- body mass much, et- connuctice microal, etval, etval cerebrovascular accident, riev- nedatus etvirus, ink- international	rtate aminotranof	arasa BML body m	ass index CI	confidence inter	val CVA corobrou	ascular accida	+ + + + +		
	ls ratio	erase, Bivii- body ma	ass much, CI-	confidence inter	val, CVA- cerebiov	ascular accide	nt, ne v - nepatit	is C virus, inte-inte	mational

		2005-2009		r.	2010-2014			2015-2019	
	OR	95% CI	p-Value	OR	95% CI	p-Value	OR	95% CI	p-Value
			<0.001			< 0.001			<0.001
	0.619	0.129 - 2.976		0.262	0.116 – 0.591		0.162	0.088 - 0.298	
	2.441	0.305 – 19.565		0.630	0.222 - 1.789		2.551	0.595 – 10.945	
	Reference			Reference			Reference		
	0.925	0.336 - 2.546		1.227	0.553 - 2.725		1.415	0.826 - 2.425	
	0.280	0.134 - 0.587		0.394	0.216 - 0.719		0.706	0.439 - 1.136	
	0.147	0.072 - 0.299		0.206	0.114 - 0.369		0.262	0.169 - 0.405	
	0.104	0.046 - 0.238		0.126	0.061 - 0.258		0.153	0.090 - 0.260	
	0.047	0.009 - 0.242		N/A			N/A		
									<0.001
							Reference		
							1.888	1.308 - 2.725	
							0.684	0.519 - 0.902	
							0.690	0.440 - 1.083	
	0.412	0.259 - 0.653	<0.001	0.465	0.304 - 0.712	<0.001	0.485	0.356 - 0.661	<0.001
				0.526	0.372 - 0.744	< 0.001	0.578	0.447 - 0.746	<0.001
	0.096	0.042 - 0.218	<0.001	0.067	0.028 - 0.159	< 0.001	0.139	0.093 - 0.208	<0.001
łL				0.221	0.131 - 0.371	< 0.001	0.363	0.252 - 0.523	<0.001
onfidence interval, HCV- hepatitis C virus, OR- odds ratio									

Conclusions

• The number of donors is increasing annually to meet the ever present need for organs for

- The donor population closely reflects the general population in the prevalence of obesity and diabetes, however the prevalence of hypertension is lower in the donor population The factors associated with donor utilization have increased over the study period–ALL factors associated with donor utilization in the most recent era (2015-2019) were present in the
- There is an increased likelihood of organ utilization from marginal donors in the most recent era (2015-2019)– including use of organs from donors over 60 years old, obese donors, those with hypertension, diabetes, or 3 or more comorbid conditions
- DCD donors account for an increasing proportion of all donors. The factors associated with DCD donor utilization are much more narrow than those for DBD donors
- There will likely be continued increase in the utilization of DCD donors as machine perfusion modalities and normothermic regional perfusion (NRP) techniques become mainstream